Companies:64525
FatCapitalist:Apple Inc. [AAPL]United States

Mind Medicine (MindMed) Inc. [MNMDCanada

NasdaqCM exchange. Sector: Healthcare. Industry: Biotechnology. Location Canada, Vancouver.
At close Fri Sep 30 2022
3.5 USD 👍0.26 (+7.43%)

At close Fri Sep 30 2022

Marketcap
1,472,593,408 USD

Marketcap

PE:.
BETA (5y):1.984
EPS:-0.184
Profits

for 5 years

384%

for 3 years

6,380%

for 2 years

6,380%

for 1 year

10%

for this year

189%
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

MindMed discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering. Learn more about our medicines and therapies today.

Mind Medicine (MindMed) Inc.
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.